• Application Note

Risperidone and 9-Hydroxyrisperidone on Oasis MCX 

Risperidone and 9-Hydroxyrisperidone on Oasis MCX 

  • Waters Corporation
Risperidone molecule structure

This is an Application Brief and does not contain a detailed Experimental section.

Abstract

This application brief highlights the separation of risperidone and 9-hydroxyrisperidone on Oasis MCX.

Introduction

Risperidone is an antipsychotic drug and is rapidly metabolized to the 9-hydroxyrisperidone metabolite in the liver. This metabolite is the predominant circulating species with same activity as the parent and therefore, must be quantitated. All analytes are bases and therefore an Oasis MCX plate was selected.

Experimental

Test Conditions

Oasis MCX 10-mg plate ( P/N 186000259)

Condition:

500 μL MeOH

Equilibrate:

500 μL H2O

Load:

500 μL (250 μL human plasma, diluted 1:1 with 4% H3PO4 in H2O)

Wash 1:

500 μL 2% FA

Wash 2:

500 μL MeOH

Elute:

250 μL (125 μL x 2) 5% NH4OH in MeOH

Options:

1. Dilute 250 μL H2O with 2% FA

2. Evaporate/ Reconstitute

3. Direct inject

Inject:

10 μL

Column:

ACQUITY UPLC BEH C18 2.1 x 50 mm, 1.7 μm

Mobile Phase A:

0.1% HCOOH in H2O

Mobile Phase B:

0.1% HCOOH in MeOH

Flow Rate:

0.3 mL /min

Injection Volume:

10.0 μ L

Column Temperature:

40 °C

Sample Temperature:

10 °C

Instrument:

ACQUITY UPLC with Quattro Premier

Gradient:

Time (min)

Profile

%A

%B

0.0

60

40

1.0

60

40

1.5

0

100

3.5

0

100

4.0

60

40

4.5

60

40

Quattro Premier

ESI+

Capillary:

3.5 kV

Source Temp.:

120 °C

Desolvation Temp.:

350 °C

Cone Gas Flow:

0 L /Hr

Desolvation Gas Flow:

700 L /Hr

Collision Cell Pressure:

2.59 e-3 mbar

Results and Discussion

Featured Products

WA60088, June 2007

Back To Top Back To Top